Anti-tumor efficacy in CT26 model and rechallenge results. (IMAGE)

InSilico Medicine

Anti-tumor efficacy in CT26 model and rechallenge results.

Caption

Preclinical studies suggest robust in vivo efficacy in mice models and induction of long-term tumor immunity, verified by CT26 rechallenge experiments. Additionally, combination potential was with a broad spectrum of treatment options, including immune checkpoint inhibitors, chemotherapies, and other targeted agents.   

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.